The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study.

Tóth E, Csupor E, Mészáros S, Ferencz V, Németh L, McCloskey EV, Horváth C

Bone25 Nov 2004Cited by 15 (Europe PMC)

PMID15664001DOI10.1016/j.bone.2004.09.003PepBankPUB-15664001

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with idiopathic osteoporosis, lumbar spine BMD rose by 3.5% with calcitonin versus 0.83% with control (P = 0.04).
In plain wordsIn men with idiopathic osteoporosis, calcitonin increased lower spine bone density more than control.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD
Study
n = 71
Comparator
Vitamin D and calcium alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily during alternate months · intranasal · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change
3.5%
calcitonin plus vitamin D and calcium group
Lumbar spine BMD change
0.83%
control group (vitamin D and calcium)
Source sentences
Summary
Compared to controls, nasal calcitonin was associated with significant increases in bone mineral density at the lumbar spine (+3.5 +/- (-4.3%) vs. +0.83 +/- 6.4%, P = 0.04) and the femoral neck (+3.2 +/- 3.9% vs. +0.68 +/- 5.7%, P = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, open label, controlled trial in 71 male patients (mean age 59 +/- 6 years) suffering from idiopathic osteoporosis (femoral neck T-score < -2.5) without vertebral deformity.
Summary · context
The study period was 18 months.
Report a problemFND-1566400101
02HumanRandomized controlled trialEfficacy outcome
In men with idiopathic osteoporosis, calcitonin increased femoral neck BMD by 3.2% versus 0.68% with control (P = 0.004).
In plain wordsIn men with idiopathic osteoporosis, calcitonin increased femoral neck bone density more than control.
Peptide
Calcitonin-salmon
Outcome
IncreaseFemoral neck BMD
Study
n = 71
Comparator
Vitamin D and calcium alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily during alternate months · intranasal · 18 monthsAs given in this study (human).
Measurements
Femoral neck BMD change
3.2%
calcitonin plus vitamin D and calcium group
Femoral neck BMD change
0.68%
control group (vitamin D and calcium)
Source sentences
Summary
Compared to controls, nasal calcitonin was associated with significant increases in bone mineral density at the lumbar spine (+3.5 +/- (-4.3%) vs. +0.83 +/- 6.4%, P = 0.04) and the femoral neck (+3.2 +/- 3.9% vs. +0.68 +/- 5.7%, P = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, open label, controlled trial in 71 male patients (mean age 59 +/- 6 years) suffering from idiopathic osteoporosis (femoral neck T-score < -2.5) without vertebral deformity.
Summary · context
The study period was 18 months.
Report a problemFND-1566400102
03HumanRandomized controlled trialEfficacy outcome
In men with idiopathic osteoporosis, radius BMD increased by 1.4% in both groups, without a significant between-group difference.
In plain wordsIn men with idiopathic osteoporosis, radius bone density did not differ significantly between calcitonin and control.
Peptide
Calcitonin-salmon
Outcome
No significant changeRadius BMD
Study
n = 71
Comparator
Vitamin D and calcium alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily during alternate months · intranasal · 18 monthsAs given in this study (human).
Measurements
Radius BMD change
1.4%
calcitonin plus vitamin D and calcium group
Radius BMD change
1.4%
control group (vitamin D and calcium)
Source sentences
Summary
No significant difference was observed at the radius between the treatment groups (+1.4 +/- 8.8% vs. +1.4 +/- 10.9%, P = 0.98).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, open label, controlled trial in 71 male patients (mean age 59 +/- 6 years) suffering from idiopathic osteoporosis (femoral neck T-score < -2.5) without vertebral deformity.
Summary · context
The study period was 18 months.
Report a problemFND-1566400103
04HumanRandomized controlled trialSafety outcome
In men with idiopathic osteoporosis, no premature discontinuations were reported with calcitonin nasal spray in this trial, compared with the control group.
In plain wordsIn men with osteoporosis, no premature discontinuations were reported with calcitonin nasal spray, compared with the control group.
Peptide
Calcitonin-salmon
Outcome
Not applicablePremature discontinuations
Study
n = 71
Comparator
Vitamin D and calcium alone
Outcome group
Adverse events · Whole body
Studied dose
200 IU daily during alternate months · intranasal · 18 monthsAs given in this study (human).
Source sentences
Summary
Treatment was well tolerated with no premature discontinuations or significant side effects compared to the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, open label, controlled trial in 71 male patients (mean age 59 +/- 6 years) suffering from idiopathic osteoporosis (femoral neck T-score < -2.5) without vertebral deformity.
Summary · context
The study period was 18 months.
Report a problemFND-1566400104
05HumanRandomized controlled trialSafety outcome
In men with idiopathic osteoporosis, calcitonin produced no significant side effects compared with control.
In plain wordsIn men with idiopathic osteoporosis, calcitonin produced no significant side effects compared with control.
Peptide
Calcitonin-salmon
Outcome
No significant changeSignificant side effects
Study
n = 71
Comparator
Vitamin D and calcium alone
Outcome group
Adverse events · Whole body
Studied dose
200 IU daily during alternate months · intranasal · 18 monthsAs given in this study (human).
Source sentences
Summary
Treatment was well tolerated with no premature discontinuations or significant side effects compared to the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, open label, controlled trial in 71 male patients (mean age 59 +/- 6 years) suffering from idiopathic osteoporosis (femoral neck T-score < -2.5) without vertebral deformity.
Summary · context
The study period was 18 months.
Report a problemFND-1566400105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.